Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Deloitte
Merck
Chubb
Johnson and Johnson
McKesson
Queensland Health
US Department of Justice
Dow
Harvard Business School

Generated: February 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,126,375

« Back to Dashboard

Summary for Patent: 5,126,375
Title: Phenethanolamine derivatives
Abstract:Phenethanolamine derivatives are disclosed of formula ##STR1## wherein m is 2 to 8; n is 1 to 7 provided that m+n is 4 to 12; Ar is phenyl or phenyl substituted by one or two halogen atoms, alkyl or alkoxy groups or by an alkylenedioxy group; R.sup.1 and R.sup.2 are hydrogen or alkyl provided that the sum total of carbon atoms in R.sup.1 and R.sup.2 is not more than 4; and the physiologically acceptable salts and solvates thereof. The compounds have a selective stimulant action at .beta..sub.2 -adrenoreceptors and may be used inter alia in the treatment of diseases associated with reversible airways obstructions such as asthma and chronic bronchitis. The compounds may be formulated in conventional manner as pharmaceutical compositions with physiologically acceptable carriers or excipients. The compounds may be prepared, for example by alkylation of an amine: ##STR2## where R.sup.3, R.sup.5 and R.sup.6 is hydrogen or a protecting group, followed by removal of any protecting group.
Inventor(s): Skidmore; Ian F. (Herts, GB2), Lunts; Lawrence H. C. (Herts, GB2), Finch; Harry (Herts, GB2), Naylor; Alan (Herts, GB2)
Assignee: Glaxo Group Ltd. (London, GB)
Application Number:07/619,899
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 5,126,375

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,126,375

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan8310477Apr 18, 1983
Japan8317087Jun 23, 1983
Japan8329568Nov 04, 1983
Japan8401889Jan 25, 1984

International Patents Family Members for US Patent 5,126,375

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 244199 ➤ Try a Free Trial
Argentina 245687 ➤ Try a Free Trial
Argentina 247721 ➤ Try a Free Trial
Austria 390611 ➤ Try a Free Trial
Austria A129184 ➤ Try a Free Trial
Australia 2706484 ➤ Try a Free Trial
Australia 573212 ➤ Try a Free Trial
Belgium 899448 ➤ Try a Free Trial
Belgium 900835 ➤ Try a Free Trial
Bulgaria 61490 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Johnson and Johnson
Citi
Covington
Farmers Insurance
Colorcon
Harvard Business School
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot